Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEPO: Xenon Inhalation and Erythropoietin Levels
NCT02129400Phase 3Terminated
- Sponsor
- RWTH Aachen University
- Start
- May 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of xenon in anemia and ischemic injury (16 arms), sponsored by RWTH Aachen University. Primary endpoint: Change from baseline in erythropoetin-level in blood. Started May 2014; status: terminated.
02
Drugs
xenon
03
Conditions
anemiaischemic injury
Beyond the preview
Go deeper on NCT02129400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129400.